33rd week of 2022 patent applcation highlights part 8 |
Patent application number | Title | Published |
20220257465 | CARDIO PULMONARY RESUSCITATION FEEDBACK SYSTEM - A CPR feedback system for assessing CPR carried out by a person on a subject and providing CPR feedback to the person, including an ECG system, a biosignal system, a CPR assessment system, and a CPR feedback unit. The CPR assessment system is configured to perform the steps (i) establish a reference ECG signal metric and a target biosignal metric, (ii) produce a CPR feedback signal, (iii) receive ECG signals measured during a plurality of chest compressions and use the ECG signals to establish a current ECG signal metric, (iv) receive biosignals and use the biosignals to establish a current biosignal metric, (v) compare the current ECG signal metric with the reference ECG signal metric and compare the current biosignal metric with the target biosignal metric, (vi) when the current ECG signal metric is less than the reference ECG signal metric and the current biosignal metric is less than the target biosignal metric, produce a CPR feedback signal, (vii) when the current ECG signal metric is less than the reference ECG signal metric and the current biosignal metric is equal to or greater than the target biosignal metric, increase the target biosignal metric and produce a CPR feedback signal advising the person to improve CPR performance, (viii) when the current ECG signal metric is equal to or greater than the reference ECG signal metric, set the reference ECG signal metric equal to the current ECG signal metric and produce a CPR feedback signal advising the person to maintain current CPR performance. | 2022-08-18 |
20220257466 | FLUID STIMULATION METHODS AND DEVICES FOR TREATING FLUID OVERLOAD - Methods for treating fluid overload in a subject comprise shifting fluids directly and non-invasively from an interstitial compartment of the subject to skin of the subject through controlled local sweating. Methods of the invention allow for removal of excess fluid from the interstitial compartment of the subject and treat fluid overload in the subject. Sweat stimulation systems comprise a chamber and first and second relative humidity sensors. The chamber is sized to fit around a body part of a subject, comprises an inlet and an outlet, and is configured such that air flows through the chamber from the inlet to the outlet. The first relative humidity sensor is operably located inside the inlet, and the second relative humidity sensor is operably located proximate the outlet. | 2022-08-18 |
20220257467 | COMPOSITION FOR PROTECTIVE COVER AND CAP - The present invention provides, for example, a protective cover composition used for preparing a cap, the cap including a cap body and a protective cover. The protective cover composition is used for preparing the protective cover, includes a styrene-based block copolymer including a styrene monomer as a constituent unit. A content ratio of the styrene monomer is 10 to 60% by mass. | 2022-08-18 |
20220257468 | MEDICAL CONTAINER WITH NFC ANTENNA - A pharmaceutical container may include a cylindrical hollow container body ( | 2022-08-18 |
20220257469 | PHARMACEUTICAL UNIT DOSE SYSTEMS FOR ORAL DRY SOLUTION AND SUSPENSION - This disclosure provides a pharmaceutical unit dose system. The unit dose system includes a unit-of-use self-dispersing dry composition for oral suspension. Also provided is a method for preparing a single unit dose of a dry pharmaceutical composition for oral administration. The unit dose system is advantageous in the convenience of use, dosing accuracy, long term storage, suspension uniformity over conventional multidose powder composition for oral suspension. | 2022-08-18 |
20220257470 | COMPONENTS OF OPEN LIQUID DRUG TRANSFER SYSTEMS AND A ROBOTIC SYSTEM EMPLOYING THEM - Presented herein are a robotic system that is configured for compounding and preparation of medications comprising non-hazardous drugs and a vented drug vial adapter. The robotic system comprises: a laminar flow cabinet; and at least one robotic arm. The vented drug vial adapter is designed to connect a drug vial to another component of a drug transfer system. The adapter comprises a hydrophobic filter that prevents passage of liquid while allowing air to pass through it and a vent hole to the atmosphere. The vent hole is located above the filter thereby allowing equalization of the internal pressure while preventing the drug from contaminating the atmosphere. | 2022-08-18 |
20220257471 | DRUG ACCOMMODATING DEVICE OF SOLID ORAL FORMULATION, AND ORAL ADMINISTRATION AND DELIVERY APPARATUS COMPRISING SAME - A drug accommodating device of a solid oral formulation and an oral administration and delivery apparatus comprising same. The drug accommodating device comprises a filtering component and a supporting component; the filtering component and the supporting component cooperate with each other to form a space used for bearing drug particles or multiple pills; the filtering component has one or more pore channels allowing a liquid to pass; the pore channels are distributed in the filtering component in an up-down intricate intersection mode; alternatively, a water-soluble polymer material layer is provided on the filtering component. Alternatively, the drug accommodating device is a cylindrical structure with a top end being an opening and a bottom part being a screen mesh; the inner surface of the screen mesh is provided with the water-soluble polymer material layer; an inner cavity having the cylindrical structure above water-soluble polymer material layer is used for accommodating the drug particles or multiple pills. The drug accommodating device can overcome the problem that fluid resistance is large when the drug particles or multiple pills are leaked and sipped. | 2022-08-18 |
20220257472 | MEDICATION DISPENSER AND METHODS - A medication dispenser is described that comprises a main body having a medication reservoir, a delivery tube, and one or more steering arms. The medication dispenser also has a cap. The medicine dispenser further has a carousel with a top platform and a bottom platform. The top platform has a top face with a sealing platform and a side face. A bottom platform of the carousel has grips. Methods of administering a medication from the medicine dispenser and manufacturing the medication dispenser are also described. | 2022-08-18 |
20220257473 | PACIFIER - A pacifier | 2022-08-18 |
20220257474 | Dental Materials Based On Polymerizable Thiourea Derivatives - Radically polymerizable dental material, which includes a combination of a hydroperoxide and a thiourea derivative according to the following Formula (I) as initiator system for the radical polymerization: | 2022-08-18 |
20220257475 | COSMETIC COMPOSITION IN THE FORM OF A COMPACT, IMPACT-RESISTANT POWDER - Pulverulent composition (Ci) in the form of a powder including, for 100% of the weight thereof: i) from 89.5% to 94.65% by weight of at least one filler (AC); ii) from 5% to 10% by weight of at least one coloured pigment (PC); iii) from 0.35% to 0.5% by weight of at least one polymer of crosslinked anionic polyelectrolyte type (P) which includes, for 100 mol %, from 65 mol % to 95 mol % of monomer units derived from partially or totally salified 2-methyl-2-[(1-oxo-2-propenyl)amino]-1-propanesulfonic acid, from 4.8 mol % to 25 mol % of monomer units derived from at least one neutral monomer chosen from the elements of the group constituted by 2-hydroxyethyl acrylate, 2-hydroxyethyl methacrylate, N,N-dialkyl acrylamides in which each of the alkyl groups includes between one and four carbon atoms, and from 0.1 mol % to 5 mol % of monomer units derived from at least one monomer of formula (I). | 2022-08-18 |
20220257476 | CONDITIONING HAIR CARE COMPOSITIONS IN THE FORM OF DISSOLVABLE SOLID STRUCTURES - The Dissolvable Solid Structure as described herein can be in the form of a fibrous structure comprising: (a) a polymeric structurant; (b) a high melting point fatty compound such as a fatty amphiphile, and (c) a cationic surfactant. The polymeric structurant has a weight average molecular weight of from about 10,000 to about 6,000,000 g/mol, and the components of the fibrous material form a homogenous material when molten. When water is added to the dissolvable solid structure at a ratio of about 5:1 a lamellar structure is formed. | 2022-08-18 |
20220257477 | HAIR CARE COMPOSITION COMPRISING ANTIDANDRUFF AGENT - A composition comprising: (i) an antidandruff agent; (ii) a wax or a wax-like substance in which said antidandruff agent is soluble or dispersible, where melting point of said wax and said substance is 30° C. to 105° C. and where said substance is not a UV absorbing sunscreen; and, (iii) a cationic polymer having weight average molecular weight of 103 Da to 107 Da, where said composition is in the form of particles of particle size 0.1 to 1000 μm and where said wax-like substance is a C13 to 35 fatty alcohol; where said wax is at least one of beeswax, Chinese wax, lanolin, shellac wax, spermaceti, bayberry wax, candelilla wax, carnauba wax, castor wax, esparto wax, Japan wax, ouricury wax, rice bran wax, soy wax, tallow tree wax, ceresin wax, montan wax, ozocerite or peat wax. | 2022-08-18 |
20220257478 | METHOD FOR DYEING KERATINOUS MATERIAL, COMPRISING THE USE OF AN ORGANOSILICON COMPOUND, A COLORED EFFECT PIGMENT AND A SEALING REAGENT I - The subject of the present disclosure is a process for dyeing keratinous material, in particular human hair, comprising the following steps:
| 2022-08-18 |
20220257479 | Gynecological vaginal wash for adjusting female vaginal microecology and preparation method thereof - A gynecological vaginal wash for adjusting female vaginal microecology and a preparation method thereof, The wash is prepared by adding a natural fragrance to acidic water with an acidic water volume concentration of 0.01-0.5% and adjusting a pH value thereof to 3.5-5.5 after disinfection. | 2022-08-18 |
20220257480 | AN ANTIPERSPIRANT COMPOSITION - The present invention relates to an anti-perspirant (AP) composition that comprises conventional metal-based AP actives, natural oil and select phenolic compounds that ensures that when such compositions are used on a body part e.g. the axilla there is minimal or no yellow coloured staining of the fabric which is worn by an individual through several use-wash-rinse-dry cycles. | 2022-08-18 |
20220257481 | ANTIBACTERIAL DEODORANT CONTAINING TITANIUM DIOXIDE PHOTOCATALYST - Provided is an antibacterial deodorant containing a titanium dioxide photocatalyst, including: a titanium dioxide photocatalyst; and a composition for antibacterial deodorization, wherein the titanium dioxide photocatalyst includes titanium dioxide (TiO | 2022-08-18 |
20220257482 | ANTI-AGING AND SKIN TONE LIGHTENING COMPOSITIONS AND METHODS FOR SAME - Embodiments of the invention are directed to compositions containing cannabinoid, cannabidiol, or cannabidiol analog for lightening or whitening skin, and methods for lightening skin tone or whitening skin by administering compositions containing cannabinoid, cannabidiol, or cannabidiol analog to the skin. | 2022-08-18 |
20220257483 | INCREASING THE STABILITY OF AGENTS FOR TREATING KERATIN MATERIAL - A process of treating keratinous material is disclosed. The process comprises applying to the keratinous material a first composition (A) and a second composition (B). The first composition (A) comprises (A1) less than about 10% by weight of water, based on the total weight of the first composition (A), and (A2) one or more organic C1-C6 alkoxy silanes and/or condensation products thereof. The second composition comprises (B1) water and (B2) one or more aromatic or aliphatic aldehydes having from 2 to 20 carbon atoms. A multicomponent packaging unit (kit-of-parts) is also provided. The kit-of-parts includes, separately prepared, a first container comprising the first composition (A), a second container comprising the second composition (B). The kit-of-parts optionally includes a third container comprising a third composition (C) comprising at least one colorant compound, and further optionally a fourth container comprising a fourth composition (D) comprising at least one film-forming polymer. | 2022-08-18 |
20220257484 | WHOLE MOUTH MALADOR CONTROL BY A COMBINATION OF ANTIBACTERIAL AND DEODORIZING AGENTS - Disclosed are oral care compositions effective to control mouth and breath malodour comprising in a pharmaceutically acceptable carrier, a combination of an antibacterial agent and a deodorizing or odor-neutralizing agent comprising a compound having the structure | 2022-08-18 |
20220257485 | PREBIOTIC COSMETIC COMPOSITIONS AND METHODS FOR THE PREPARATION THEREOF - The present disclosure relates to topical prebiotic cosmetic compositions and methods for their preparation. Benefits of the compositions disclosed herein can include a health benefit of promoting a favorable balance of microorganisms in the body's integumentary system. | 2022-08-18 |
20220257486 | AQUEOUS SURFACTANT COMPOSITIONS AND SOAP BARS - Suggested are surfactant compositions comprising: One or more alpha-sulfofatty acid disalts (A) of general formula (I), RICH (SO3M1) COOM2 (I), wherein the radical R 1 denotes a linear or branched alkyl or alkenyl radical having 6 to 18 C atoms and the radicals M 1 and M 2-independently of one another-are selected from the group H, Li, Na, K, Ca/2, Mg/2, Ammonium and alkanolamines and one or more polysaccharides (B) selected from the group consisting of dextrin and its derivatives, starch and its derivatives, cellulose and its derivatives, preferably one or more dextrins (B) of the general formula (II), (II) in which n is an integer between 3 and 200. | 2022-08-18 |
20220257487 | SULPHATE-FREE CONCENTRATED RHEO-FLUIDIFYING FOAMING COMPOSITION AND USES THEREOF - The present invention relates to a surfactant composition comprising: | 2022-08-18 |
20220257488 | COMPOUNDS, COMPOSITIONS CONTAINING SAME, AND USE THEREOF FOR PROMOTING HAIR GROWTH - Provided are preparation and use of novel compounds available as main ingredients of a composition for promoting hair growth, wherein the novel compounds are 9-deoxo-31-O-demethyl-prolyl-FK506, 9-deoxo-36,37-dihydro-FK506, 31-O-demethyl-36,37-dihydro-FK506, 9-deoxo-31-O-demethyl-36,37-dihydro-FK506, 9-deoxo-FK520, 31-O-demethyl-FK520, 9-deoxo-31-O-demethyl-FK520, 9-deoxo-FK523, and 9-deoxo-31-O-demethyl-FK523. | 2022-08-18 |
20220257489 | Compositions and Methods for the Removal of Tattoos - The present invention provides a method for removing a tattoo in a region of skin the method comprises administering to a least a portion of the tattoo a composition comprising an effective amount of a bisphosphonate and at least one pharmaceutically acceptable excipient to at least cause fading of the tattoo in said region. | 2022-08-18 |
20220257490 | METHOD FOR DYEING KERATINOUS MATERIAL, COMPRISING THE USE OF AN ORGANOSILICON COMPOUND, A COLORED EFFECT PIGMENT AND A FILM-FORMING POLYMER IV - A process for dyeing keratinous material, in particular human hair, is provided. The process includes applying an agent (a) to the keratinous material, the agent (a) including at least one organic silicon compound. An agent (b) is applied to the keratinous material. The agent (b) includes (b1) at least one coloring compound including at least one effect pigment including i) a substrate platelet, ii) a metal oxide (hydrate) layer provided on the surface of the substrate platelet, iii) a metal particle carrier layer provided on the surface of the metal oxide (hydrate) layer, and iv) metal particles provided on the surface of the metal particle carrier layer, and (b2) at least one film-forming polymer. | 2022-08-18 |
20220257491 | Prebiotic Oral Care Compositions and Methods - The disclosure relates to methods of enhancing beneficial oral bacteria and decreasing harmful oral bacteria comprising administering oral care compositions comprising a saccharide prebiotic, e.g., selected from D-mannose, N-acetyl-D-mannosamine and mixtures thereof; and oral care compositions for use in such methods. The disclosure also relates to methods of using prebiotic oral care compositions, methods of screening, and methods of manufacture. | 2022-08-18 |
20220257492 | TOPICAL FORMULATIONS OF RECOMBINANT COLLAGENS - This disclosure provides methods of improving firmness, elasticity, brightness, hydration, tactile texture or visual texture of skin. The method comprises topically applying non-naturally occurring truncated collagen molecules to skin. | 2022-08-18 |
20220257493 | NAIL TREATMENT COMPOSITION - Cosmetic compositions for treating the nails include a water-insoluble cellulose polymer, one or more additional film-formers, plasticizer, and a urea compound. Methods of using the compounds to treat nails are also provided. | 2022-08-18 |
20220257494 | METHODS AND COMPOSITIONS FOR MICROFLILLNG THE SKIN WITH HYALURONIC ACID USING MICROCHANNEL TECHNOLOGY - The present invention provides methods of administering a composition comprising hyaluronic acid to a subject's skin, comprising providing an effective amount of hyaluronic acid in solid form; constituting the hyaluronic acid in an aqueous solution; and administering the solution comprising hyaluronic acid to the subject's skin. | 2022-08-18 |
20220257495 | COMPOSITIONS AND METHODS FOR IMPROVING SKIN APPEARANCE - Injectable compositions and methods of treating skin can help improve hydration, elasticity and/or texture of the skin. The compositions can be based on crosslinked hyaluronic acid matrices made with low molecular weight hyaluronic acids. | 2022-08-18 |
20220257496 | HAIR COSMETIC COMPOSITION CONTAINING AQUEOUS GELLING AGENT, AND METHOD FOR PRODUCING AQUEOUS GELLING AGENT AND HAIR COSMETIC COMPOSITION - A hair cosmetic composition including component (A), which is an aqueous gelling agent represented by general formula (1) described in the specification, and a component (B), which includes either one of or both of a cationic surfactant and a cationic polymer, wherein the component (A) presents a viscosity of an aqueous solution containing 1 mass % of at 25° C. of 1,000 to 5,000 mPa·s and a clouding point of the aqueous solution containing 1 mass % of component (A) of 60° C. to 80° C., and has a weight average molecular weight of 10,000 to 30,000; a method for producing the aqueous gelling agent and a method for producing the hair cosmetic composition are provided. | 2022-08-18 |
20220257497 | COSMETIC COMPOSITION - Provided is a cosmetic composition with excellent storage stability, feel during use and ultraviolet light blocking effects, in which an inorganic ultraviolet light blocking agent comprising a hydrophobic fine particulate metal oxide, e.g., hydrophobic fine particulate zinc oxide can be uniformly and stably dispersed in an aqueous phase, and in which a reduction in viscosity of a formulation is suppressed even when the structure of the hydrophobic fine particulate metal oxide is dispersed in the aqueous phase. The cosmetic composition comprises (A) a carboxylic acid modified silicone having a specific structure, (B) a water-soluble thickening agent, (C) a basic compound, and (D) a hydrophobic fine particulate metal oxide. The cosmetic composition is useful as a sunscreen cosmetic composition. | 2022-08-18 |
20220257498 | DYE COMPOSITION COMPRISING A COMBINATION OF NATURAL DYEING AGENTS INCLUDING AN EXTRACT OF LAWSONIA INERMIS - The disclosure relates to a dye composition comprising a combination of natural dyeing agents including an extract of | 2022-08-18 |
20220257499 | COSMETIC COMPOSITION COMPRISING A YEAST HYDROLYSATE - A cosmetic composition including a yeast hydrolysate and to the use thereof in cosmetics, for promoting moisturization of the skin and/or protecting human skin against drying out and/or improving the barrier function and/or for an anti-ageing effect. The yeast hydrolysate is obtained by a process that includes solubilization of the yeast in water, enzymatic hydrolysis, separation of the soluble and insoluble phase and recovery of the soluble phase, enzymatic inactivation, and optionally concentration and sterilizing filtration. | 2022-08-18 |
20220257500 | USE OF A HYDRO-ALCOHOLIC EXTRACT OF EVENING PRIMROSE FOR HYDRATING SKIN AND INCREASING BARRIER FUNCTION - The present invention relates to a hydro-alcoholic extract of above-ground parts of evening primrose ( | 2022-08-18 |
20220257501 | Cosmetic Preparations Comprising Natural Activators - The present invention relates to the use of a combination of plant extracts from the genera | 2022-08-18 |
20220257502 | CONTROLLED RELEASE FORMULATION DELIVERY DEVICE - A desired elution profile can be identified, and a delivery device designed to effect the desired elution profile, such as by selecting materials for the constituent components of the delivery device, designing a structure of the delivery device and its constituent components, and selecting a content of formulations, to provide for the designed elution profile at particular expected conditions or at particular times or both. | 2022-08-18 |
20220257503 | Surface Modified Gas Vesicles, Preparation and Applications thereof - The present application provides surface-modified novel targeting GVs (such as PH-GVs), lipid GVs and lipid targeting GVs, preparation methods therefor, and applications thereof in tumor diagnosis, imaging and treatment. | 2022-08-18 |
20220257504 | TREATMENT APPROACH BY TARGETED DELIVERY OF BIOACTIVE MOLECULES - A method of treating a bacterial infection in a subject includes administering at least a first finely divided (particulate) material, which may have at least a second material, the first material is not bioresorbable or very slowly bioresorable and the second material or materials are bioresorbable at a higher rate than the first material, allowing a certain period of time to pass in order to provide for the first particulate material to be exposed to the body and/or second material or materials to be wholly or partly absorbed by the body of the subject, and administering one or more pharmaceutically active compounds. The first material is optionally pre-loaded or soaked with one or more pharmaceutically active compounds, and the second material is optionally pre-loaded or soaked with one or more pharmaceutically active compounds. The pharmaceutically active compound is a compound capable of treating or ameliorating a bacterial infection. | 2022-08-18 |
20220257505 | TREATMENT OF OCULAR DISEASES USING ENDOTHELIN RECEPTOR ANTAGONISTS - The present disclosure relates to the discovery that certain diseases of the eye that profoundly affect the human visual system and, as a result, quality of life, may be treated using Edonentan or A-182086. Edonentan or A-182086 can be used alone or in combination with an intra-ocular pressure (IOP) reducing agent, a neuroprotective agent, an anti-VEGF agent, or all, for example. Using Edonentan or A-182086, alone or in combination with an additional agent, provides increased perfusion to the retina in certain diseases and reduces damage to retinal cells. | 2022-08-18 |
20220257506 | Alkaline Drink - A drink comprising in admixture stable alkaline water and a statin or a statin precursor, the pH of the water being from 8 to 10.5. The drink may include other ingredients including CBD or THC. | 2022-08-18 |
20220257507 | VISCOUS COMPOSITION - Provided is a viscous composition that does not lose its ease of handling even after long-term storage and is easily returned to a uniform composition even if layer separation occurs, despite containing a high concentration of a partially neutralized product of a polymer containing ethylenically unsaturated carboxylic acid units. | 2022-08-18 |
20220257508 | SUSPENSIONS AND DILUENTS FOR METRONIDAZOLE AND BACLOFEN - Suspensions of metronidazole or baclofen and/or salts or ester derivative thereof, such as metronidazole benzoate, are disclosed. The suspension my include metronidazole or baclofen, and/or a salt or ester derivative thereof a hydrocolloid stabilizer, simethicone emulsion, a buffer, such as sodium citrate, (dihydrate), a preservative, a thickening agent, a sweetener, and water. | 2022-08-18 |
20220257509 | METHODS OF TREATING SKIN DISORDERS - Disclosed herein are methods for treatment of a skin disorders using pharmaceutical compositions that reduces the expression of and/or inhibit the activity of various genes including chemokine (C-X-C motif) ligands such as CXCL13 and XCL1, and matrix-metalloproteinases such as MMP12 and MMP13. The pharmaceutical compositions effectively act on epidermal differentiation and proliferation as well as on innate and adaptive immune cells in pathogenesis of skin disorders such as acne. | 2022-08-18 |
20220257510 | Compositions for Nanoemulsion Delivery Systems - The present disclosure provides a pharmaceutically acceptable, stable, and optically clear oil-in-water nanoemulsions (intensity-averaged diameter<100 nm) with an oil phase comprising >10% w/v of long chain triglyceride, total surfactant and cosurfactant concentration less than that of oil phase and without the use of alcohol as cosolvent in the aqueous phase. The nanoemulsions of this disclosure have extremely favorable particle size distribution, optical clarity, and product stability against Ostwald ripening with high levels of oil concentrations. Poorly water soluble, therapeutically active agents and others can be incorporated in the nanoemulsion systems to improve their solubility/stability in aqueous medium or to enhance their delivery for use in pharmaceutical, food, cosmetic, and other applications by oral, intravenous, subcutaneous, intra muscular, inhalation, nasal, topical, ocular, and transdermal routes. | 2022-08-18 |
20220257511 | NANOVESICLES - A process for the preparation of unilamellar vesicles, wherein a unilamellar vesicle comprises an amphiphilic membrane enclosing an aqueous core; and compositions comprising unilamellar vesicles. | 2022-08-18 |
20220257512 | MULTIVALENT DELIVERY OF IMMUNE MODULATORS BY LIPOSOMAL SPHERICAL NUCLEIC ACIDS FOR PROPHYLACTIC OR THERAPEUTIC APPLICATIONS - Liposomal spherical nucleic acids that function as multivalent immune modulators are provided according to the invention. The liposomal spherical nucleic acids of the invention are useful prophylactic and therapeutic applications as well as research and diagnostic indications. | 2022-08-18 |
20220257513 | INSOLUBLE ACTIVE SUBSTANCE CARRIER COMPRISING TRANSFERSOME - A carrier for an insoluble active substance is disclosed. The carrier contains transfersome that includes an insoluble active substance in a high content and can stabilize the insoluble active substance. In addition, since the carrier has a small particle size, it is possible to promote the delivery of the insoluble active substance into a body of subject. Therefore, a cosmetic or pharmaceutical composition containing the carrier for an insoluble active substance can maximize the effect of the active substance. | 2022-08-18 |
20220257514 | MONOSACCHARIDE-TAGGED NANO-LIPOSOME DRUG DELIVERY SYSTEM, THE MANUFACTURE AND USE FOR DRUG TARGETING DELIVERY THEREOF - The present invention relates to a monosaccharide-tagged nano-liposome, which is characterized that the targeting monosaccharide is conjugated to cholesterol and the monosaccharide-conjugated cholesterol is incorporate into the phospholipid bilayer. The nano-liposome of present invention exhibits the ability to carry the loaded drug to target cells, such as cancer cells and cancer stem cells in a tumor tissue, and may be internalized by endocytosis to produce direct cytotoxicity or suppress stemness gene expression, so as to avoid toxicity to normal cells and effectively improve the therapeutic effect of cancer clinical medication and radiation therapy. | 2022-08-18 |
20220257515 | Drug delivery methods and compositions - The present application provides liposomal compositions containing anti-cancer agents and tumor-targeting lipopeptides. The present application also provides nanodiamond complexes and particles as carriers for anti-cancer agents. | 2022-08-18 |
20220257516 | THERAPEUTIC CONSTRUCTS FOR CO-DELIVERY OF MITOTIC KINASE INHIBITOR AND IMMUNE CHECKPOINT INHIBITOR - Disclosed herein are therapeutic constructs including a delivery particle, at least one mitotic kinase inhibitor, and at least one immune checkpoint inhibitor. Also disclosed are therapeutic constructs including a mitotic kinase inhibitor, an immune checkpoint inhibitor, and a chemical linker. These therapeutic constructs cause cancer death by both therapeutic and immune effects and promote targeted delivery of more therapeutics to the surviving cancer cells in a positive feed-back loop. They enhance therapeutic index of free drugs and can be used intratumorally or systemically. This strategy can treat broad cancer types and is particular useful for cancer without obvious receptors for cancer-targeted delivery of otherwise toxic therapeutics. | 2022-08-18 |
20220257517 | POWDER COMPOSITION COMPRISING A COPOLYMER MIXTURE AND A WATER-SOLUBLE CELLULOSE - A powder composition contains 50 to 95% by weight of a copolymer mixture A of a copolymer 1 and a copolymer 2, and 50 to 5% by weight of a water-soluble cellulose B. The copolymer 1 contains 5 to 60% by weight of polymerized units of methacrylic acid and 95 to 40% by weight of C | 2022-08-18 |
20220257518 | LONG-LASTING FORMULATION CONTAINING RIVASTIGMINE, AND METHOD FOR PREPARING SAME - The present invention relates to a sustained release microsphere for long-lasting injectable formulations comprising one or more active ingredients selected from the group consisting of rivastigmine and pharmaceutically acceptable poorly soluble salts thereof and a biodegradable polymer, and a long-lasting injectable formulation for preventing or treating Alzheimer's disease comprising the same and a method for preparing the microsphere, and it can reduce side effects of the patient's gastrointestinal tract, which are frequently seen in conventional oral administration agents, and increase the adaptability of taking medicine, thereby maximizing the therapeutic effect, by providing a long-lasting injectable formulation comprising a rivastigmine sustained release microsphere, which has a high content while effectively controlling the initial burst drug release. | 2022-08-18 |
20220257519 | RAPIDLY DISINTEGRATING SOLID ORAL DOSAGE FORMS CONTAINING DASATINIB - The instant application relates to the field of pharmaceutical compositions comprising dasatinb. Furthermore, the instant application relates to a method of treating proliferative disorders in a patient in need thereof, comprising administering a therapeutically effective amount of said compositions. | 2022-08-18 |
20220257520 | MONOMETHYLFUMARATE PRODRUG COMPOSITIONS - The present invention provides pharmaceutical compositions comprising compounds of Formula (I), and methods of treating neurological disorders comprising administering to a subject in need thereof a pharmaceutical composition comprising a compound of Formula (I). | 2022-08-18 |
20220257521 | METHOD FOR MICRO-ENCAPSULATION OF NATURAL INGREDIENTS BY MEANS OF CONTACTING WITH SUPERCRITICAL GAS - The invention provides a method for microencapsulating a natural ingredient in an encapsulation material, comprising: | 2022-08-18 |
20220257522 | DOSE DUMPING RESISTANT PHARMACEUTICAL COMPOSITIONS COMPRISING VERINURAD - Disclosed herein are pharmaceutical formulations comprising verinurad or a pharmaceutically acceptable salt thereof that are resistant to alcohol-induced dose dumping and may be used in therapeutic and/or prophylactic methods. | 2022-08-18 |
20220257523 | COMPOSITE DRUG PARTICLES AND USES THEREOF - Provided herein are particles comprising compounds having a steroid core structure, or salts or esters thereof, and transition metal nanoparticles. Also provided herein are compositions comprising the particles, and methods of using the particles, for example in methods of treating liver disorders or for fat reduction. | 2022-08-18 |
20220257524 | NANOCOMPOSITE PARTICLE AND USES THEREOF - Disclosed herein is a nanocomposite particle comprising a core-shell-shell nanoparticle, an encapsulated nanorod linked with the core-shell-shell nanoparticle, and a lipid layer encapsulating the core-shell-shell nanoparticle and the encapsulated nanorod. The core-shell nanoparticle comprises a phosphor core, an inner shell layer, an outer shell layer, and a cationic polymer. The encapsulated nanorod comprises a nanorod, and a mesoporous scaffold. According to embodiments of the present disclosure, the encapsulated nanorod is linked with the core-shell-shell nanoparticle via an electrostatic interaction between the cationic polymer and the mesoporous scaffold. Also disclosed are the uses of the nanocomposite in treating diseases, for example, cancers. | 2022-08-18 |
20220257525 | DRUG DELIVERY SYSTEM FOR TREATMENT OF CANCER - Described herein is a hydrophobic anti-cancer drug encapsulated into poly (alkyl cyanoacrylate) nanoparticles and their use in cancer treatments by intracavitary rout of administration such as intraperitoneal administration. | 2022-08-18 |
20220257526 | NANOPARTICLES FOR TREATMENT OF POSTERIOR SEGMENT OCULAR DISEASES AND CONDITIONS - The present invention concerns nanoparticles useful for treating posterior segment ocular diseases or conditions, such as macular degeneration and diabetic retinopathy; compositions comprising the nanoparticles; methods for producing the nanoparticles; and methods for treating posterior segment ocular diseases or conditions, comprising administering the nanoparticles or compositions to the ocular posterior segment of an afflicted eye. | 2022-08-18 |
20220257527 | ORALLY ADMINISTRABLE FILMS COMPRISING POORLY WATER SOLUBLE ACTIVE INGREDIENTS AND PREPARATION THEREOF - Disclosed herein are orally administrable mucoadhesive film compositions which comprise a poorly water soluble bioactive material(s) in a high loading, an alginate as a major film-forming polymer, and an emulsifier. Also provided is a method for preparing such films, including the step of homogenizing a composition comprising these components. | 2022-08-18 |
20220257528 | ROTIGOTINE-CONTAINING PATCH - The present invention provides a rotigotine-containing patch comprising:
| 2022-08-18 |
20220257529 | USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPTIC SPASMS - The present invention relates to the use of cannabidiol (CBD) for the treatment of epileptic spasms. In particular the epileptic spasms that are treated are associated with Tuberous Sclerosis Complex (TSC). In a further embodiment the epileptic spasm is treated with CBD in combination with clobazam. Preferably the CBD used is in the form of a botanically derived purified CBD which comprises greater than or equal to 98% (w/w) CBD and less than or equal to 2% (w/w) of other cannabinoids. The other cannabinoids present are THC at a concentration of less than or equal to 0.1% (w/w); CBD-C1 at a concentration of less than or equal to 0.15% (w/w); CBDV at a concentration of less than or equal to 0.8% (w/w); and CBD-C4 at a concentration of less than or equal to 0.4% (w/w). The botanically derived purified CBD preferably also comprises a mixture of both trans-THC and cis-THC. Alternatively, a synthetically produced CBD is used. Where the CBD is given concomitantly with one or more other anti-epileptic drugs (AED) including clobazam, the CBD may be formulated for administration separately, sequentially or simultaneously with one or more AED or the combination may be provided in a single dosage form. | 2022-08-18 |
20220257530 | ANTIMICROBIAL FORMULATIONS FOR THE TREATMENT OF VETERINARY HOOF INFECTIONS - There is provided a composition comprising an organic material and at least a first surfactant which following addition of an aqueous solution to the composition can form a biphasic system, wherein the biphasic system is useful for the treatment of or prevention of hoof infections. Also provided is a biphasic system useful for the treatment of or prevention of hoof infections, wherein the biphasic system comprises the composition and an aqueous phase wherein the composition is dispersed as droplets within the aqueous phase. | 2022-08-18 |
20220257531 | COMPOSITIONS AND METHODS FOR TREATMENT OF A FIBROTIC DISEASE | 2022-08-18 |
20220257532 | COMPOSITIONS CONTAINING PTEROSIN COMPOUND AND DERIVATIVES THEREOF ACTIVE INGREDIENTS FOR PREVENTION OR TREATMENT OF DEGENERATIVE BRAIN DISEASES - The present invention relates to compositions containing a pterosin compound and derivatives thereof as active ingredients for the prevention or treatment of degenerative brain diseases and, more specifically, to a pharmaceutical composition for the prevention or treatment of degenerative brain diseases and a food composition for the prevention or alleviation of degenerative brain diseases, each of which contains a pterosin compound defined by chemical formula 1 or a derivative thereof as an active ingredient. A method of the present invention can be favorably used to provide a therapeutic agent for preventing or treating degenerative brain diseases, a food for alleviating degenerative brain diseases, or a functional food for the promotion of cognitive functions, by using a pterosin compound extracted from Pteridium aquilinum and derivatives thereof. | 2022-08-18 |
20220257533 | METHODS AND COMPOSITIONS FOR TREATMENT OF INFLAMMATION AND OXIDATIVE STRESS - Compounds, compositions, and methods for treatment of, or prophylaxis against, inflammation and/or oxidative stress are disclosed. | 2022-08-18 |
20220257534 | NAIL HARDENING COMPOSITION AND METHOD OF US - A composition and method for treatment of brittle, broken, cracked or otherwise damaged nail and hoof plates. The composition is an aqueous-organic medium containing a non-covalent complex of a diamine and an organic acid or an aqueous-organic medium with a diamine alone. | 2022-08-18 |
20220257535 | INK FORMULATION AND MANUFACTURE THEREOF - An ink for marking living tissue, the ink comprising: a carrier; an analgesic; an antiseptic; an antihistamine; and a coloring agent. A method of preparing an ink formulation for marking living tissue, comprising the steps of: mixing the pharmaceutically accepted carrier, analgesic, antiseptic, and antihistamine to form a carrier preservative compound; adding the pharmaceutically accepted coloring agent to the carrier preservative compound; mixing the pharmaceutically accepted coloring agent to the carrier preservative compound to form said ink formulation. A carrier preservative compound for removing ink from living tissue comprising: a carrier; an analgesic; an antiseptic; and an antihistamine. | 2022-08-18 |
20220257536 | KETAMINE AND KETAMINE/NAP FOR TREATMENT OF ADNP SYNDROME AND RELATED NEUROLOGICAL CONDITIONS - The invention is directed to a method of increasing the expression of Activity-Dependent Neuroprotector Protein (ADNP) in at least one mammalian cell showing insufficient ADNP expression levels, comprising administering to the at least one mammalian ceil an effective amount of ketamine or a combination of ketamine and ADNP-Derived Neuroprotective Peptide (NAP). | 2022-08-18 |
20220257537 | DILUTE READY TO USE LARGE VOLUME CONTAINERS OF PHENYLEPHRINE - Ready to use large volume containers of dilute solutions of phenylephrine having excellent shelf stability. | 2022-08-18 |
20220257538 | DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION - This disclosure relates to dosage forms containing an enantiomerically enriched or pure bupropion such as an enantiomeric excess of (S)-bupropion, enantiomerically enriched (S)-bupropion, or enantiomerically pure (S)-bupropion and methods of using these dosage forms. These dosage forms may be administered to human beings in a reduced amount as compared to the amount of racemic bupropion that would be administered in the same situation. | 2022-08-18 |
20220257539 | COMPOSITIONS COMPRISING EPHEDRINE OR AN EPHEDRINE SALT AND METHODS OF MAKING AND USING SAME - The present disclosure provides compositions comprising ephedrine sulfate ready for immediate use in a clinical setting, and methods of making and using same. | 2022-08-18 |
20220257540 | COMPOSITIONS AND METHODS FOR TREATMENT OF HEPATITIS B VIRUS INFECTION - A pharmaceutical composition and kits thereof for treatment of HBV infection comprises colchicine and CYP3A4/P-gp inhibitor. | 2022-08-18 |
20220257541 | Lacosamide for the Treatment of ADD/ADHD - The present invention relates to the treatment of attention deficit hyperactivity disorder (ADHD) or attention deficit disorder (ADD) using lacosamide or functionally equivalent analogues thereof. The treatment may result in one or more of: (i) an improvement of cognitive function; (ii) an improvement of cognitive performance; (iii) a reduction in hyperactivity; (iv) an improvement in the circadian rhythm and/or sleep quality; and/or (v) an improvement in mood. | 2022-08-18 |
20220257542 | PHARMACEUTICAL COMPOSITION COMPRISING TRIMETHOBENZAMIDE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING NEUROPATHIC PAIN - The present invention relates to a pharmaceutical composition comprising trimethobenzamide or a pharmaceutically acceptable salt thereof as an active ingredient for preventing or treating neuropathy. Trimethobenzamide, when administered in combination with tramadol, exhibits the effect of significantly reducing pain in a neuropathy animal model and as such, can be advantageously used for treatment of neuropathy. | 2022-08-18 |
20220257543 | DISPERSIBLE FORMULATIONS OF N-((R)-2,3-DIHYDROXYPROPOLY)-3,4-DIFLUORO-2-(2-FLUORO-4-IODO-PHENYLAMINO)- -BENZAMIDE AND USES THEREOF - The present disclosure relates to dispersible pharmaceutical compositions comprising N—((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide, and, optionally, a pharmaceutically acceptable carrier. | 2022-08-18 |
20220257544 | COMPOSITION AND METHOD FOR ATTENUATING NEUROINFLAMMATION, AMYLOIDOPATHY AND TAUOPATHY - The present invention features compositions and methods for preventing or treating neuroinflammation, amyloidopathy or tauopathy by inhibiting Acyl-CoA:Cholesterol Acyltransferase activity, in particular with brain-permeable inhibitors encapsulated in a stealth liposome-based nanoparticle. Stealth liposome-based nanoparticles for reducing or attenuating amyloidopathy or tauopathy are also provided. | 2022-08-18 |
20220257545 | pH STABLE UREA COMPOSITION AND USE THEREOF - The invention includes a composition for the treatment of a skin disorder, in particular topical treatment. Embodiment of the composition include at least 20% w/w urea, and a pH stabilizing component, where the pH stabilizing component includes a hydroxy acid such as lactic acid and a polyhydroxy acid or lactone thereof, such as gluconolactone. The composition has an initial pH of less than 6.2 and the composition has a pH less than about 6.2 after storage for at least four weeks. The invention is also a method of treating a skin or nail disorder by topically administering the composition. The invention is also a method of improving pH stability of a urea formulation that has greater than about 20% w/w urea. | 2022-08-18 |
20220257546 | KETONE BODIES ENCLOSED IN MICROBEADS - The invention relates to a composition comprising ketone bodies contained in microbeads, in particular, for use in maintaining an increased blood concentration of ketone bodies in a subject for a prolonged period of time, preferably for the use as a medicament, food for special medical purposes/medical food or nutraceutical/food supplement. It further relates to methods to produce a composition comprising ketone bodies contained in microbeads. Also provided are non-medical uses of microbeads/ketone bodies/compositions of the invention. | 2022-08-18 |
20220257547 | ORALLY ADMINISTRABLE MODIFIED-RELEASE PHARMACEUTICAL DOSAGE FORM - The present invention relates to orally administrable modified-release pharmaceutical dosage forms comprising sodium (3S)-3-(4-chloro-3-{[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}phenyl)-3-cyclopropylpropanoate and to processes for preparing the dosage forms and to their use for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiac, renal and pulmonary disorders, disorders of the central nervous system, fibrotic and inflammatory disorders and metabolic disorders. | 2022-08-18 |
20220257548 | ORAL COMBINATION DRUG FORMULATION COMPRISING A NON-STEROIDAL ANTI-INFLAMMATORY DRUG AND A COMPLEMENTARY LOW DOSE OF TRANEXAMIC ACID FOR THE TREATMENT OF MENSTRUAL PAIN ACCOMPANIED WITH EXCESSIVE MENSTRUAL BLOOD LOSS - A method for relieving menstrual pain and reducing menstrual blood loss in a female is provided. The method comprises administering to the female an oral combination drug formulation comprising a first therapeutically effective dose of a non-steroidal anti-inflammatory drug (NSAID) and a second complementary low dose of tranexamic acid, wherein the NSAID is formulated to relieve the menstrual pain and to reduce a volume of menstrual blood loss of the female, wherein the dose of tranexamic acid ranges from 200 mg to 250 mg per oral combination drug formulation. | 2022-08-18 |
20220257549 | METHOD FOR TREATMENT OF PARKINSON'S DISEASE - Disclosed is a method for the treatment of a neurological or movement disorder, e.g., Parkinson's disease, in an individual in need thereof, by parenteral administration of levodopa and a dopa decarboxylase inhibitor (DDCI), such as carbidopa, benserazide or any combination thereof, concomitantly with oral administration of levodopa, a DDCI, such as carbidopa, benserazide, or any combination thereof. | 2022-08-18 |
20220257550 | REDUCING THE VIRAL ACTIVITY OF ELAFIBRANOR WITH RIBOFLAVIN OR DHA - The present invention relates to a combination of elafibranor with either riboflavin or DHA as antiviral agent. The bacteriophage T4 titer on | 2022-08-18 |
20220257551 | AMORPHOUS SOLID FORM OF COMPOUNDS CONTAINING S-N-VALERYL-N-{[2'-(1H-TETRAZOLE-5-YL)-BIPHENYL-4-YL]-METHYL}-VALINE AND (2R,4S)-5-BIPHENYL-4-YL-4-(3-CARBOXY-PROPIONYLAMINO)-2-METHYL-PENTANOIC ACID ETHYL ESTER MOIETIES AND SODIUM CATIONS - An amorphous solid form of a compound comprising of the angiotensin receptor antagonist (ARB) valsartan, the neutral endopeptidase inhibitor (NEPi) (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methylpentanoic acid ethyl ester and sodium cations is provided. This is compound is useful for the treatment of hypertension and/or heart failure. | 2022-08-18 |
20220257552 | METHODS OF PRESCREENING AND TREATING BREAST CANCERS WITH SELECTIVE ANDROGEN RECEPTOR MODULATORS - This invention relates to methods of prescreening and treatment of a breast cancer in a subject, and the subject can be either a male or female subject, including methods of prescreening then treating: metastatic breast cancer; refractory breast cancer; AR-positive breast cancer; AR-positive refractory breast cancer; AR-positive metastatic breast cancer; AR-positive and ER-positive breast cancer; triple negative breast cancer; advanced breast cancer; breast cancer that has failed treatments with selective estrogen receptor modulator (SERM) (tamoxifen, toremifene, raloxifene), gonadotropin-releasing hormone (GnRH) agonist (goserelin), aromatase inhibitor (AI) (letrozole, anastrozole, exemestane), fulvestrant, cyclin-dependent kinase 4/6 (CDK 4/6) inhibitor (palbociclib (Ibrance), ribociclib (Kisqali), abemaciclib (Vorzenio), trilaciclib, lerociclib), alpelisib (Piqray) (an inhibitor of phosphatidylinositol-3-kinase subunit alpha (PI3Kα)), mTOR inhibitor (everolimus), poly ADP ribose polymerase (PARP) inhibitor (olaparib (Lynparza) or talazoparib (Talzenna)), human epidermal growth factor receptor 2 (HER2) kinase inhibitor (lapatinib, neratinib (Nerlynx), dacomitinib (Vizimpro), or tucatinib (Tukysa)), HER2 antibody (trastuzumab (Herceptin), pertuzumab (Perjeta), margetuximab-cmkb (Margenza)), HER2 antibody drug conjugate (HER2 ADC) (am-trastuzumab-deruxtecan-nxki (Enhertu), ado-trastuzumab emtansine (Kadcyla), or pertuzumab/trastuzumab/hyaluronidase-zzxf (Phesgo)), atezolizumab (Tecentriq) (PD-L1 blocking antibody), pembrolizumab (Keytruda) (PD-L1 blocking antibody), sacituzumab govitecan (Trodelvy) (antibody drug conjugate for TNBC), bevacizumab (Avastin), and/or sabizabulin or a pharmaceutically acceptable salt thereof; metastasis in a subject suffering from breast cancer; HER2-positive; and/or ER mutant expressing breast cancer, comprising administering to the subject a therapeutically effective amount of a selective androgen receptor modulator (SARM) compound as described herein. | 2022-08-18 |
20220257554 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF A CANCER - A pharmaceutical combination comprising (A): a polyunsaturated fatty acid and (B): a chemotherapeutic agent compound for the simultaneous, separate or sequential use in the treatment of a cancer in a human patient. | 2022-08-18 |
20220257555 | DERIVATIVES OF KORORMICIN USEFUL AS ANTIBIOTICS - An antibiotic compound of formula (I): | 2022-08-18 |
20220257556 | DOSING REGIMENS FOR ORAL COMPLEMENT FACTOR D INHIBITORS - Disclosed are compounds and pharmaceutically acceptable salts and prodrugs thereof, which are inhibitors of the complement system. Also provided are oral dosage forms comprising such a compound, salt, or prodrug. Also disclosed are methods of using the compounds, salts, and prodrugs, and oral dosage forms thereof, in the treatment or prevention of a disease or condition characterized by aberrant complement system activity (e.g., paroxysmal nocturnal hemoglobinuria). | 2022-08-18 |
20220257557 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING NEUROLOGICAL DISEASES - The present disclosure relates to a pharmaceutical composition for preventing or treating neurological disease containing a pyrano[2,3-f]chromene derivative compound, a pharmaceutically acceptable salt thereof, or a solvate thereof. The pharmaceutical composition is capable of enhancing or protecting the functions of various enzymes including paraoxonase. | 2022-08-18 |
20220257558 | METHODS FOR RESTORING STEM CELL POOLS AND REDUCING EPIGENETIC AGE - Disclosed are methods and compositions for reducing the epigenetic age of organisms, especially that of adult humans, which provide for proliferating endogenous stem cells, removing aberrant epigenetic marks from chromosomes and mitochondrial DNA, and replacement of senescent cells. | 2022-08-18 |
20220257559 | INTESTINAL MICROBIOME-IMPROVING COMPOSITION INCLUDING ELLAGIC ACID AS ACTIVE INGREDIENT - Proposed is an intestinal microbiome-improving composition containing ellagic acid as an active ingredient. The ellagic acid inhibits the growth of harmful bacteria such as Verrucomicrobia and Bacteroidetes attributable to alcohol intake and increases the growth of beneficial bacteria such as Firmicutes, thereby controlling intestinal microbes. As a result, the ellagic acid exhibits the effect of inhibiting an increase in a plasma endotoxin level, an increase in an intestinal TNF-α level, an increase in intestinal oxidative stress, a decrease in expression of intestinal TJ and AJ proteins, liver fat accumulation, an increase in plasma ALT, an increase in triglycerides, and hepatic oxidative stress and apoptosis. The composition containing ellagic acid as an active ingredient is provided as an intestinal microbe-improving composition and a preventive and therapeutic preparation for alcoholic fatty liver. | 2022-08-18 |
20220257560 | COMPOSITIONS AND METHODS USING CANNABINOIDS FOR TREATING STAMMERING/STUTTERING AND SYMPTOMS OF TOURETTE SYNDROME - This invention relates to compositions and methods for treating stammering/stuttering and Tourette syndrome (TS) in humans, using a formulation comprising of a combination of a | 2022-08-18 |
20220257561 | COMPOSITIONS AND METHODS FOR IMPROVING WELLNESS - A composition for improving wellness of a human is provided herein. The composition includes, but is not limited to, a flavonoid. The composition further includes, but is not limited to, a prodrug of cysteine. The composition further includes, but is not limited to, a pharmaceutically acceptable carrier. The pharmaceutically acceptable carrier includes, but is not limited to, an ionic liquid to form a solubilizing matrix. The flavonoid exhibits an improved solubility in the pharmaceutically acceptable carrier in the presence of the solubilizing matrix as compared to solubility of a flavonoid in a pharmaceutically acceptable carrier substantially free of the solubilizing matrix. | 2022-08-18 |
20220257562 | METHOD FOR IMPROVING ENDOMETRIOSIS AND METHOD FOR PRODUCING A MATERIAL USED THEREFOR - A method for improving endometriosis includes administrating a composition containing aglycon type isoflavones and a pharmaceutically acceptable carrier to mammal subject in need of treatment of endometriosis in an amount effective for treating endometriosis, wherein the aglycon type isoflavones are composed of daidzein, genistein, and glycitein. | 2022-08-18 |
20220257563 | Nitrile-Containing Antiviral Compounds - The invention relates to compounds of Formula I″ | 2022-08-18 |
20220257564 | PHARMACEUTICAL COMPOSITIONS FOR TREATING CYSTIC FIBROSIS - A pharmaceutical composition comprising Compound I: | 2022-08-18 |
20220257565 | Microsphere-Based Injectible Celecoxib Formulation - This invention provides a biodegradable microsphere, wherein the microsphere (i) has a diameter of from 1 ?m to 500 ?m; (ii) comprises a polylactic-co-glycolic acid copolymer (PLGA) matrix; (iii) carries pharmaceutical celecoxib; and (iv) when present in a suitable joint-related tissue, releases celecoxib for at least one month. This invention also provides related injectable formulations, methods for treating joint-related disorders, and kits. | 2022-08-18 |